Monika Kirsch1, Sandra A Mitchell2, Fabienne Dobbels3, Georg Stussi4, Ethan Basch5, Jorg P Halter6, Sabina De Geest7. 1. Institute of Nursing Science, University of Basel, Switzerland; Department of Haematology, University Hospital Basel, Switzerland. 2. Outcomes Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, United States. 3. Health Services and Nursing Research, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium. 4. Department of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland. 5. Cancer Outcomes Research Program, Lineberger Comprehensive Cancer Center, University of North Carolina, United States. 6. Department of Haematology, University Hospital Basel, Switzerland. 7. Institute of Nursing Science, University of Basel, Switzerland; Health Services and Nursing Research, Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium. Electronic address: sabina.degeest@unibas.ch.
Abstract
PURPOSE: The aim of this sequential mixed methods study was to develop a PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events)-based measure of the symptom experience of late effects in German speaking long-term survivors of allogeneic stem cell transplantation (SCT), and to examine its content validity. METHODS: The US National Cancer Institute's PRO-CTAE item library was translated into German and linguistically validated. PRO-CTCAE symptoms prevalent in ≥50% of survivors (n = 15) and recognized in its importance by SCT experts (n = 9) were identified. Additional concepts relevant to the symptom experience and its consequences were elicited. Content validity of the PROVIVO (Patient-Reported Outcomes of long-term survivors after allogeneic SCT) instrument was assessed through an additional round of cognitive debriefing in 15 patients, and item and scale content validity indices by 9 experts. RESULTS: PROVIVO is comprised of a total of 49 items capturing the experience of physical, emotional and cognitive symptoms. To improve the instrument's utility for clinical decision-making, questions soliciting limitations in activities of daily living, frequent infections, and overall well-being were added. Cognitive debriefings demonstrated that items were well understood and relevant to the SCT survivor experience. Scale Content Validity Index (CVI) (0.94) and item CVI (median = 1; range 0.75-1) were very high. CONCLUSIONS: Qualitative and quantitative data provide preliminary evidence supporting the content validity of PROVIVO and identify a PRO-CTCAE item bundle for use in SCT survivors. A study to evaluate the measurement properties of PROVIVO and to examine its capacity to improve survivorship care planning is underway.
PURPOSE: The aim of this sequential mixed methods study was to develop a PRO-CTCAE (Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events)-based measure of the symptom experience of late effects in German speaking long-term survivors of allogeneic stem cell transplantation (SCT), and to examine its content validity. METHODS: The US National Cancer Institute's PRO-CTAE item library was translated into German and linguistically validated. PRO-CTCAE symptoms prevalent in ≥50% of survivors (n = 15) and recognized in its importance by SCT experts (n = 9) were identified. Additional concepts relevant to the symptom experience and its consequences were elicited. Content validity of the PROVIVO (Patient-Reported Outcomes of long-term survivors after allogeneic SCT) instrument was assessed through an additional round of cognitive debriefing in 15 patients, and item and scale content validity indices by 9 experts. RESULTS: PROVIVO is comprised of a total of 49 items capturing the experience of physical, emotional and cognitive symptoms. To improve the instrument's utility for clinical decision-making, questions soliciting limitations in activities of daily living, frequent infections, and overall well-being were added. Cognitive debriefings demonstrated that items were well understood and relevant to the SCT survivor experience. Scale Content Validity Index (CVI) (0.94) and item CVI (median = 1; range 0.75-1) were very high. CONCLUSIONS: Qualitative and quantitative data provide preliminary evidence supporting the content validity of PROVIVO and identify a PRO-CTCAE item bundle for use in SCT survivors. A study to evaluate the measurement properties of PROVIVO and to examine its capacity to improve survivorship care planning is underway.
Authors: Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch Journal: JAMA Oncol Date: 2015-11 Impact factor: 31.777
Authors: Ashley Wilder Smith; Sandra A Mitchell; Cheryl K De Aguiar; Claudia Moy; William T Riley; Molly V Wagster; Ellen M Werner Journal: Transl Behav Med Date: 2016-09 Impact factor: 3.046
Authors: A Tichelli; S Gerull; A Holbro; A Buser; G Nair; M Medinger; D Heim; J P Halter; J R Passweg Journal: Bone Marrow Transplant Date: 2017-06-26 Impact factor: 5.483
Authors: Elisabeth Simoes; Andrea Kronenthaler; Christine Emrich; Monika A Rieger; Kristin Katharina Rall; Norbert Schäffeler; Hanna Hiltner; Esther Ueding; Sara Y Brucker Journal: Biomed Res Int Date: 2014-12-03 Impact factor: 3.411
Authors: Kerstin A Kessel; Rebekka C E Grosser; Kim Melanie Kraus; Hans Hoffmann; Markus Oechsner; Stephanie E Combs Journal: BMC Cancer Date: 2020-05-19 Impact factor: 4.430
Authors: Mark A Samaan; Polychronis Pavlidis; Sophie Papa; Nick Powell; Peter M Irving Journal: Nat Rev Gastroenterol Hepatol Date: 2018-03-07 Impact factor: 46.802